A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 4, 2004, Pages 1215-1227

  Li, Lingyun ^a,b   Wartchow, Charles A ^b   Danthi, S Narasimhan ^c   Shen, Zhimin ^b   Dechene, Neal ^b   Pease, John ^b   Choi, H Steven ^b   Doede, Tina ^b   Chu, Pauline ^a   Ning, Shoucheng ^a   Lee, Daniel Y ^a   Bednarski, Mark D ^c   Knox, Susan J ^a,d  

^a STANFORD UNIVERSITY   (United States)

^b Targesome Inc   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Flk 1; Integrin; Nanoparticle; Radiotherapy

Indexed keywords

CHEMOTHERAPY; PATIENT TREATMENT; TUMORS;

ANGIOGENSIS; TUMOR GROWTH;

RADIOTHERAPY;

4 [2 (3,4,5,6 TETRAHYDROPYRIMIDIN 2 YLAMINO)ETHOXY]BENZOYL 2(5) AMINOETHYLSULFONYLAMINO BETA ALANINE; ANGIOGENESIS INHIBITOR; INTEGRIN ANTAGONIST; MONOCLONAL ANTIBODY; NANOPARTICLE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; YTTRIUM 90;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLON ADENOCARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG TARGETING; FEMALE; MELANOMA; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; IN SITU NICK-END LABELING; INTEGRINS; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, NUDE; MODELS, ANIMAL; NANOTECHNOLOGY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PENTETIC ACID; RECEPTORS, VITRONECTIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 12144288759     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.057     Document Type: Article

References (38)

1. Ausprunk D.H., Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 14:1977;53-65.
2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G. H. A. Clowes Memorial Award lecture. Cancer Res. 46:1986;467-473.
3. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 333:1995;1757-1763.
4. Denekamp J. Review article Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 66:1993;181-196.
5. Ranieri G., Gasparini G. Angiogenesis and angiogenesis inhibitors A new potential anticancer therapeutic strategy. Curr Drug Targets Immune Endocr Metabol Disord. 1:2001;241-253.
6. Felding-Habermann B., Mueller B.M., Romerdahl C.A., et al. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest. 89:1992;2018-2022.
7. Bello L., Zhang J., Nikas D.C., et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas. Neurosurgery. 47:2000;1185-1195.
8. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264:1994;569-571.
9. Max R., Gerritsen R.R., Nooijen P.T., et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer. 71:1997;320-324.
10. Sipkins D.A., Cheresh D.A., Kazemi M.R., et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 4:1998;623-626.
11. Haubner R., Wester H.J., Burkhart F., et al. Glycosylated RGD-containing peptides Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 42:2001;326-336.
12. van Hagen P.M., Breeman W.A., Bernard H.F., et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 90:2000;186-198.
13. Haubner R., Wester H.J., Reuning U., et al. Radiolabeled alpha(v)beta3 integrin antagonists A new class of tracers for tumor targeting. J Nucl Med. 40:1999;1061-1071.
14. Haubner R., Wester H.J., Weber W.A., et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:2001;1781-1785.
15. Phillips W.T. Delivery of gamma-imaging agents by liposomes. Adv Drug Deliv Rev. 37:1999;13-32.
16. Wessels B.W., Rogus R.E. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys. 11:1984;638-645.
17. Mausner L.F., Srivastava S.C. Selection of radionuclides for radioimmunotherapy. Med Phys. 20:1993;503-509.
18. Jain RK. Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin Oncol 2002;29(6 Suppl. 16):3-9.
19. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 55:2000;15-36.
20. Yang J.C., Hawarth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 349:2003;427-434.
21. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 21:2003;60-65.
22. Niethammer A.G., Xiang R., Becher J.C., et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 8:2002;1369-1375.
23. Ramakrishnan S., Olson T.A., Bautch V.L., et al. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 56:1996;1324-1330.
24. Stratmann A., Machein M.R., Plate K.H. Anti-angiogenic gene therapy of malignant glioma. Acta Neurochir Suppl (Wien). 68:1997;105-110.
25. Lin P., Sankar S., Shan S., et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 9:1998;49-58.
26. Shepherd F.A. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer. 34:(Suppl. 3):2001;S81-S89.
27. Hood J.D., Bednarski M., Frausto R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2002;2404-2407.
28. Storrs R.W., Tropper F.D., Li H.Y., et al. Paramagnetic polymerized liposomes as new recirculating MR contrast agents. J Magn Reson Imaging. 5:1995;719-724.
29. Brooks P.C., Montgomery A.M., Rosenfeld M., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
30. Brooks P.C., Stromblad S., Klemke R., et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 96:1995;1815-1822.
31. Petitclerc E., Stromblad S., von Schalscha T.L., et al. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 59:1999;2724-2730.
32. Gutheil J.C., Campbell T.N., Pierce P.R., et al. Targeted antiangiogenic therapy for cancer using Vitaxin A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 6:2000;3056-3061.
33. Posey J.A., Khazaeli M.B., DelGrosso A., et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm. 16:2001;125-132.
34. DeNardo S.J., Burke P.A., Leigh B.R., et al. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm. 15:2000;71-79.
35. Burke P.A., DeNardo S.J., Miers L.A., et al. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 62:2002;4263-4272.
36. Geng L., Donnelly E., McMahon G., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61:2001;2413-2419.
37. Ning S., Laird D., Cherrington J.M., et al. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res. 157:2002;45-51.
38. Janssen M.L., Oyen W.J., Dijkgraaf I., et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 62:2002;6146-6151.